Publications by authors named "Monica Gayoso-Rey"
The primary objective of this study was to conduct a cost-utility analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in real-world, comparing their use with standard care for managing cardiovascular disease. A multicenter prospective study was conducted across 12 Spanish hospitals from May 2020 to April 2022, involving 158 patients with hypercholesterolemia or atherosclerotic cardiovascular disease. This study assessed health-related quality of life (QoL) using the EQ-5D-3L questionnaire.
View Article and Find Full Text PDFArticle Synopsis
- Hepatocellular carcinoma, a leading cause of cancer deaths, is primarily treated with sorafenib, and this study evaluates its effectiveness and toxicity in real-world settings.
- A total of 36 patients were studied, revealing an average overall survival of 8.5 months and common adverse effects including constitutional, gastrointestinal, and dermatological issues.
- The results indicate that while survival outcomes in clinical practice align with clinical trials, the toxicity profile showed unexpected variations.
Introduction: The cognitive safety of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has been established in clinical trials, but not yet in real-world observational studies. We assessed the cognitive function in patients initiating PCSK9i, and differences in cognitive function domains, to analyze subgroups by the low-density lipoprotein cholesterol (LDL-C) achieved, and differences between alirocumab and evolocumab.
Methods: This has a multicenter, quasi-experimental design carried out in 12 Spanish hospitals from May 2020 to February 2023.
Background: Colorectal cancer is the ninth leading cause of death in Spain. The latest therapeutic developments in the advanced stages of this disease are the oral drugs trifluridine/tipiracil and regorafenib.
Objective: Results of clinical trials (CTs) are not in real conditions and therefore, we want to study the effectiveness and the safety profile in the usual clinical practice and compare it with the bibliography.
Objectives: MEMOGAL study (NCT04319081) is aimed at evaluating changes in cognitive function in patients treated with PCSK9 inhibitors (PCSK9i). This is the first analysis: (1) discussion about the role of the Hospital Pharmacists during the pandemic, and also the assessment of the impact of COVID-19 in the lipid control; (2) descriptive analysis; (3) effectiveness in LDL cholesterol (LDL-c) reduction of alirocumab and evolocumab; (4) communicate PCSK9i safety.
Material And Methods: It is a prospective Real-World Evidence analysis of patients that take PCSK9i for the first time in the usual clinical practice, and they are included after the first dispensation in the public pharmacy consultations of 12 Hospitals in Galicia from May 2020 to April 2021.
Article Synopsis
- The study assessed the effectiveness of a treat-and-extend (T&E) treatment plan using ranibizumab for macular edema (MO) caused by branch retinal vein occlusion (BRVO) in 20 patients over two years.
- Patients showed significant improvements in best corrected visual acuity (BCVA) and central macular thickness (CMT), with average BCVA improving from 0.60 to 0.29 and CMT decreasing from 559.85 μm to 305.85 μm.
- The results indicated that complete responders required fewer injections compared to incomplete responders, highlighting T&E's potential for effective treatment with reduced intervention frequency.
Article Synopsis
- Adalimumab is a biological therapy for chronic inflammatory diseases, and there are increasing biosimilars available, necessitating evidence on the safety and efficacy of switching between reference adalimumab and its biosimilars.
- A systematic review of studies from 2004 to 2021 identified 21 relevant studies involving 2,802 patients across various conditions, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
- The findings indicate that switching between reference adalimumab and biosimilars does not significantly affect efficacy, safety, or immunogenicity, suggesting similar outcomes for different adalimumab biosimilars and potential applicability to other rheumatic diseases.
Purpose: To evaluate the effectiveness, adverse reactions, and adherence to treatment of hypolipidemic inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9is) in a context of real clinical practice.
Methods: We present an observational, retrospective, descriptive, multicenter study of patients with hypercholesterolemia who began treatment with PCSK9is between January 2017 and December 2019, with a minimum treatment period of 3 months. The main variable we recorded was the frequency of cardiovascular events (cardiovascular death, myocardial infarction, stroke, coronary revascularization, and hospitalization for unstable angina) in patients treated with PCSK9is.
Objective: The objective of this study was to assess the results of applying Lean Methodology in the design of a standardized medication storage model in hospitalization departments.
Method: Descriptive and retrospective study conducted between September 2017 and January 2019 in a tertiary level hospital. The Pharmacy Service led the creation of a multidisciplinary team.
Background: Although the electronic prescribing software is the same for all hospitals of a regional health service, each has its own drug database, which it is responsible for maintaining. The aim of this study was to develop a consensus to standardize the hospital drug database of the electronic prescribing software, and to apply this tool to the electronic prescribing system of an oncology outpatient clinic of a Spanish tertiary-level hospital. Additionally, we sought to analyze the impact of the implemented actions on the health care services provided.
View Article and Find Full Text PDFObjective: To analyse the factors leading to greater satisfaction among patients attending the outpatient hospital pharmacy (OPh).
Methods: A cross-sectional study was conducted of patients attending the OPh of a 1250-bed university hospital. A self-administered questionnaire for measuring outpatients' satisfaction was developed.
Background: The care transition is the time when more medication errors occur. The aim of this study is to analyze the usefulness of a pharmacotherapeutic report model at hospital discharge to prevent medication errors and to simplify pharmacotherapy during a patient's transition from the hospital to primary care.
Methods: Prospective study including patients diagnosed with chronic obstructive pulmonary disease who were admitted to a short-stay unit or an emergency room.